Jupiter Neurosciences (JUNS) Stock Price, News & Analysis

Company Overview

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Key Stats

• Today's Range: $1.50 to $1.60
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 114,943 shs
• Average Volume: 131,794 shs
• Market Capitalization: $52.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Jupiter Neurosciences Stock Analysis - MarketRank™

Jupiter Neurosciences scored higher than 5% of companies evaluated by MarketBeat, and ranked 946th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Jupiter Neurosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Jupiter Neurosciences are expected to decrease in the coming year, from ($0.06) to ($0.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jupiter Neurosciences is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jupiter Neurosciences is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jupiter Neurosciences has a P/B Ratio of 11.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.28% of the float of Jupiter Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Jupiter Neurosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jupiter Neurosciences does not currently pay a dividend.

Dividend Growth

Jupiter Neurosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.28% of the float of Jupiter Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Jupiter Neurosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Jupiter Neurosciences this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for JUNS on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

1 people have added Jupiter Neurosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Jupiter Neurosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,626.00 in company stock and sold $0.00 in company stock.

JUNS Stock Analysis - Frequently Asked Questions

How were Jupiter Neurosciences' earnings last quarter?

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) announced its earnings results on Monday, August, 18th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07).

When did Jupiter Neurosciences IPO?

Jupiter Neurosciences (JUNS) raised $11 million in an IPO on Tuesday, December 3rd 2024. The company issued 2,800,000 shares at a price of $4.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO.

Company Calendar

• Last Earnings: 8/18/2025
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:JUNS
• CIK: 1679628
• Web: www.jupiterorphan.com
• Phone: 561 406 6154
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -835.24%
• Return on Assets: -155.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.07
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $230 thousand
• Price / Sales: 230.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 11.69

Miscellaneous

• Outstanding Shares: 34,830,000
• Free Float: N/A
• Market Cap: $52.94 million
• Optionable: Not Optionable
• Beta: N/A